Last reviewed · How we verify
Oleogel-S10
Oleogel-S10 is a topical oleogel formulation containing birch bark extract that promotes wound healing and tissue repair through anti-inflammatory and antimicrobial properties.
Oleogel-S10 is a topical oleogel formulation containing birch bark extract that promotes wound healing and tissue repair through anti-inflammatory and antimicrobial properties. Used for Acute wounds (cuts, abrasions, minor surgical wounds), Chronic wounds and ulcers.
At a glance
| Generic name | Oleogel-S10 |
|---|---|
| Also known as | Sericare®, Episalvan, Filsuvez |
| Sponsor | Chiesi Farmaceutici S.p.A. |
| Drug class | Topical wound healing agent |
| Modality | Small molecule |
| Therapeutic area | Dermatology / Wound Care |
| Phase | Phase 3 |
Mechanism of action
Oleogel-S10 combines an oil-based gel vehicle with standardized birch bark extract (betulin and related compounds), which exerts anti-inflammatory effects and supports the natural wound healing process. The formulation is designed to create an optimal microenvironment for epithelialization and tissue regeneration while protecting the wound from external contamination.
Approved indications
- Acute wounds (cuts, abrasions, minor surgical wounds)
- Chronic wounds and ulcers
Common side effects
- Local skin irritation
- Allergic contact dermatitis
- Application site reactions
Key clinical trials
- A Study to Learn About the Safety and Efficacy of the Drug Oleogel-S10 in Japanese Patients With Epidermolysis Bullosa (PHASE3)
- A Study of Oleogel-S10 Gel for the Treatment of Radiation Dermatitis in People With Breast Cancer (PHASE2)
- Phase III Efficacy and Safety Study of Oleogel-S10 in Epidermolysis Bullosa (PHASE3)
- Oleogel-S10 in Wound Healing of Split-Thickness Skin Graft Donor Sites (BSG-12) (PHASE3)
- Oleogel-S10 in Wound Healing of Inherited Epidermolysis Bullosa (BEB-10) (PHASE2)
- Oleogel-S10 in Wound Healing of Split-Thickness Skin Graft Donor Sites (BSH-12) (PHASE3)
- Oleogel-S10 Versus Standard of Care in Healing of Grade 2a Burn Wounds (PHASE3)
- The Efficacy and Tolerability of Oleogel-S-10 in Patients With Actinic Keratoses (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |